Molecular biology progress of small cell lung cancer

doi:10.3760/cma.j.issn.1673422X.2018.02.013

Abstract

Abstract: Small cell lung cancer (SCLC) is typified by early recurrence and metastasis associated with many genetic changes. The drug ROVAT composed of the DLL3 antibody Rovalpituzumab and the cytotoxic drug Tesirine achieves the tumorkilling effect by releasing the Tesirine when bound to DLL3. Nfib promotes the SCLC metastasis by altering the structure of the chromosome. The PRAP, EZH2 and Wee1 inhibitors inhibit the DNA damage repair to improve the antitumor activity of chemotherapeutic drugs. Combination of Ipilimumab and Nivolumab can activate the human immune system to exert antitumor effect.

Key words: Carcinoma, small cell, Immunotherapy, Targeted therapy

MENG Ling, WEI Yong-Chang, XIE Cong-Hua. Molecular biology progress of small cell lung cancer[J]. Journal of International Oncology, 2018, 45(2): 115-118.

References

［1］ Hare F, Giri S, Patel JK, et al. A populationbased analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy［J］. Springerplus, 2015, 4: 138. DOI: 10.1186/s400640150913y. ［2］ Stone EC, Zhou C, International Association for the Study of Lung Cancer Tobacco Control Committee. Slowing the titanic: China′s epic struggle with tobacco［J］. J Thorac Oncol, 2016, 11(12): 20532065. DOI: 10.1016/J.JTHO.2016.07.020. ［3］ Vanharanta S, Shu W, Brenet F, et al. Epigenetic expansion of VHLHIF signal output drives multiorgan metastasis in renal cancer［J］. Nat Med, 2013, 19(1): 5056. DOI: 10.1038/nm.3029. ［4］ Denny SK, Yang D, Chuang CH, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility［J］. Cell, 2016, 166(2): 328342. DOI: 10.1016/j.cell.2016.05.052. ［5］ Semenova EA, Kwon MC, Monkhorst K, et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients［J］. Cell Rep, 2016, 16(3): 631643. DOI: 10.1016/j.celrep.2016.06.020. ［6］ Wu N, Jia D, Ibrahim AH, et al. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer［J］. Oncotarget, 2016, 7(36): 5751457524. DOI: 10.18632/oncotarget.11583. ［7］ Heng YH, Zhou B, Harris L, et al. NFIX regulates proliferation and migration within the murine SVZ neurogenic niche［J］. Cereb Cortex, 2015, 25(10): 37583778. DOI: 10.1093/cercor/bhu253. ［8］ Piper M, Barry G, Harvey TJ, et al. NFIBmediated repression of the epigenetic factor Ezh2 regulates cortical development［J］. J Neurosci, 2014, 34(8): 29212930. DOI: 10.1523/JNEUROSCI.231913.2014. ［9］ Hsu YC, Osinski J, Campbell CE, et al. Mesenchymal nuclear factor ⅠB regulates cell proliferation and epithelial differentiation during lung maturation［J］. Dev Biol, 2011, 354(2): 242252. DOI: 10.1016/j.ydbio.2011.04.002. ［10］ Chen KS, Lim JWC, Richards LJ, et al. The convergent roles of the nuclear factor Ⅰ transcription factors in development and cancer［J］. Cancer Lett, 2017, 410: 124138. DOI: 10.1016/j.canlet.2017.09.015. ［11］ Chang CY, Pasolli HA, Giannopoulou EG, et al. NFIB is a governor of epithelialmelanocyte stem cell behaviour in a shared niche［J］. Nature, 2013, 495(7439): 98102. DOI: 10.1038/nature11847. ［12］ Dooley AL, Winslow MM, Chiang DY, et al. Nuclear factor Ⅰ/B is an oncogene in small cell lung cancer［J］. Genes Dev, 2011, 25(14): 14701475. DOI: 10.1101/gad.2046711. ［13］ Sung MH, Baek S, Hager GL. Genomewide footprinting: ready for prime time?［J］. Nat Methods, 2016, 13(3): 222228. DOI: 10.1038/nmeth.3766. ［14］ George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer［J］. Nature, 2015, 524(7563): 4753. DOI: 10.1038/nature14664. ［15］ Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3targeted antibodydrug conjugate eradicates highgrade pulmonary neuroendocrine tumorinitiating cells in vivo［J］. Sci Transl Med, 2015, 7(302): 302ra136. DOI: 10.1126/scitranslmed.aac9459. ［16］ Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3targeted antibodydrug conjugate, in recurrent smallcell lung cancer: a firstinhuman, firstinclass, openlabel, phase 1 study［J］. Lancet Oncol, 2017, 18(1): 4251. DOI: 10.1016/S14702045(16)305654. ［17］ Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1［J］. Cancer Discov, 2012, 2(9): 798811. DOI: 10.1158/21598290.CD120112. ［18］ Poirier JT, Gardner EE, Connis N, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2［J］. Oncogene, 2015, 34(48): 58695878. DOI: 10.1038/onc.2015.38. ［19］ Gardner EE, Lok BH, Schneeberger VE, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2SLFN11 axis［J］. Cancer Cell, 2017, 31(2): 286299. DOI: 10.1016/j.ccell.2017.01.006. ［20］ Hirai H, Arai T, Okada M, et al. MK1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNAdamaging agents, including 5fluorouracil［J］. Cancer Biol Ther, 2010, 9(7): 514522. ［21］ Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. MK1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53deficient pancreatic cancer xenografts［J］. Clin Cancer Res, 2011, 17(9): 27992806. DOI: 10.1158/10780432.CCR102580. ［22］ Guertin AD, Martin MM, Roberts B, et al. Unique functions of CHK1 and WEE1 underlie synergistic antitumor activity upon pharmacologic inhibition［J］. Cancer Cell Int, 2012, 12(1): 45. DOI: 10.1186/147528671245. ［23］ Lal S, Zarei M, Chand SN, et al. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner［J］. Sci Rep, 2016, 6: 33323. DOI: 10.1038/srep33323. ［24］ Sharma P. Immune checkpoint therapy and the search for predictive biomarkers［J］. Cancer Journal, 2016, 22(2): 68. DOI: 10.1097/PPO.0000000000000185. ［25］ Antonia SJ, LopezMartin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent smallcell lung cancer (CheckMate 032): a multicentre, openlabel, phase 1/2 trial［J］. Lancet Oncol, 2016, 17(7): 883895. DOI: 10.1016/S14702045(16)300985. ［26］ Reck M, Luft A, Szczesna A, et al. Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensivestage smallcell lung cancer［J］. J Clin Oncol, 2016, 34(31): 37403748. DOI: 10.1200/JCO.2016.67.6601. ［27］ Weiskopf K, Jahchan NS, Schnorr PJ, et al. CD47blocking immunotherapies stimulate macrophagemediated destruction of smallcell lung cancer［J］. J Clin Invest, 2016, 126(7): 26102620. DOI: 10.1172/JCI81603. ［28］ Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma［J］. N Engl J Med, 2012, 366(10): 925931. DOI: 10.1056/NEJMoa1112824. ［29］ Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic nonsmall cell lung cancer［J］. Cancer Immunol Res, 2013, 1(6): 365372. DOI: 10.1158/23266066.CIR130115.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[7]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[8]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[9]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[10]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[13]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[14]	Wang Ting, Li Wenqian, Xie Youbang. Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells [J]. Journal of International Oncology, 2023, 50(8): 503-507.
[15]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.